O7.3 Osteoporosis

Patients with COPD are at increases risk for fracture due to the disease itself, the use of high dose corticosteroids and coexisting risk factors such as hypogonadism (induced by corticosteroid therapy itself in high doses in men and women), immobilisation reduced muscle mass and other factors. These patients may have reduced bonemineral density (BMD) due to a reduction in bone formation and perhaps increased bone resorbtion, the latter being primarily due to the underlying disease itself.

A systematic review  of 58 studies (8,753 COPD patients) found a mean prevalence of 38% (95% CI 34 to 43) for osteoporosis in patients with COPD, with increasing odds ratios for osteoporosis associated with lower BMI and sarcopenia (Chen 2019), indicating that people with COPD are at special risk of osteoporotic fracture.  High dose corticosteroids, coexisting risk factors such as hypogonadism (induced by corticosteroid therapy itself in high doses in men and women), physical inactivity, repeated periods of immobilisation from hospital admissions, and dairy food avoidance health beliefs are all potential contributory risk factors. The presence of such factors is an indication for bone densitometry.  Assessment of vitamin D status, and other risk factors such as coexisting illnesses that may influence the skeleton (e.g. primary hyperparathyroidism) may also be required.

Patients with vertebral compression fractures, visualised on a lateral chest x-ray, have been demonstrated to have more frequent admissions, longer length of hospital stay, and increased mortality in the two years after admission (Pascual-Guardia 2017) [evidence level III-2].  These could be looked for opportunistically even if primarily investigating for causes of pulmonary deteriorations, hence leading to bone densitometry and treatment.

There are contradictory findings of a small but deleterious effect of inhaled corticosteroids at conventional doses on fracture risk.  Triamcinolone was associated with reduced BMD in the Lung Health Study (Lung Health Study Research Group 2000) [evidence level II].  However a  separate study by Ferguson et al (Ferguson 2009) demonstrated that the combination of salmeterol and  fluticasone 1000 micrograms daily had no increase in decline in bone mineral density over three years in compared with placebo in the subgroup of patients whose bone density was measured [evidence level II].

Guidelines on the currently recommended screening, prevention and treatments of osteoporosis, including corticosteroid-induced osteoporosis are available elsewhere including the eTG guidelines on Osteoporosis and minimal trauma fractures.